Gain Therapeutics
GANX
20 hedge funds and large institutions have $3.74M invested in Gain Therapeutics in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 3 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
0.16% less ownership
Funds ownership: 10.21% → 10.06% (-0.16%)
5% less capital invested
Capital invested by funds: $3.95M → $3.74M (-$215K)
13% less funds holding
Funds holding: 23 → 20 (-3)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$62.5K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$39.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$9.9K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.71K |
| 5 |
BlackRock
New York
|
+$6.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TI
Telemetry Investments
New York
|
-$84.4K |
| 2 |
CM
CM Management
Gulf Breeze,
Florida
|
-$46.9K |
| 3 |
WAAG
Wealth Alliance Advisory Group
Wichita,
Kansas
|
-$19.5K |
| 4 |
JP Morgan Chase
New York
|
-$2K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$923 |
GANX Hedge Fund Activity: Q4 2022 in Review
20 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q4 2022, worth a combined $3.74M — down 5.4% from $3.95M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of GANX and 1 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 6 added.
The largest buyer was Bridgeway Capital Management, adding an estimated $62.5K. The largest seller was Telemetry Investments, cutting an estimated $84.4K.
- 20 institutional investors held Gain Therapeutics (GANX) as of Q4 2022, down from 23 in Q3 2022.
- Funds reported $3.74M of Gain Therapeutics stock for Q4 2022, down 5.4% quarter-over-quarter.
- 1 fund opened new Gain Therapeutics positions in Q4 2022 and 3 closed out, a net change of -2 holders.
- The largest Gain Therapeutics buyer in Q4 2022 was Bridgeway Capital Management, an estimated $62.5K added.
- The largest Gain Therapeutics seller in Q4 2022 was Telemetry Investments, an estimated $84.4K sold.
Based on aggregated 13F filings for Q4 2022.